Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

The offerings reflect an increase in IPO activity that could continue, as four other biotechs recently outlined plans to go ...

FDA formally announced the end of the tirzepatide shortage in a Declaratory Order issued to Eli Lilly & Co. (“Lilly”). Lilly ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Novo Nordisk A/S soared the most since August 2023 after an experimental shot delivered as much as 22% weight loss in an ...

Contrary to what we are led to believe, investors can only spend compound returns, not average returns. Nevertheless, the average returns are so often mentioned by those seeking to promote an ...

Lexaria Bioscience Corp., a global innovator in drug delivery platforms, has announced partial final results showcasing the ...

Zepbound is the newest GLP-1 medication to be approved by the Food and Drug Administration (FDA) for weight loss. It’s available only by prescription for people with a body mass index (BMI) of ...

Medicare drug plans can now cover Eli Lilly & Co.’s obesity drug Zepbound as a treatment for obstructive sleep apnea, news that’s expected to prove a big boost for the drug company.

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Per the partial data released from that phase 3b clinical trial, over 72 weeks of once-weekly treatment with either Zepbound or Wegovy, patients taking Zepbound lost 20.2% of their weight on ...